Iterum Therapeutics (NASDAQ:ITRM) & Can-Fite BioPharma (NYSE:CANF) Critical Review

Can-Fite BioPharma (NYSE:CANF) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, institutional ownership and profitability.

Insider and Institutional Ownership

21.0% of Can-Fite BioPharma shares are held by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are held by institutional investors. 0.8% of Can-Fite BioPharma shares are held by company insiders. Comparatively, 2.0% of Iterum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Can-Fite BioPharma has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 2.96, indicating that its stock price is 196% more volatile than the S&P 500.

Profitability

This table compares Can-Fite BioPharma and Iterum Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Can-Fite BioPharma	N/A	N/A	N/A
Iterum Therapeutics	N/A	N/A	-65.54%

Analyst Ratings

This is a summary of current ratings and recommmendations for Can-Fite BioPharma and Iterum Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Can-Fite BioPharma	0	1	2	0	2.67
Iterum Therapeutics	1	2	0	0	1.67

Can-Fite BioPharma currently has a consensus price target of $44.00, suggesting a potential upside of 2,511.28%. Given Can-Fite BioPharma’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Can-Fite BioPharma is more favorable than Iterum Therapeutics.

Valuation and Earnings

This table compares Can-Fite BioPharma and Iterum Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Can-Fite BioPharma	$405,000.00	4.45	-$7.63 million	($14.80)	-0.11
Iterum Therapeutics	$390,000.00	4.10	-$24.77 million	($0.75)	-0.04

Can-Fite BioPharma has higher revenue and earnings than Iterum Therapeutics. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Can-Fite BioPharma beats Iterum Therapeutics on 8 of the 12 factors compared between the two stocks.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.